

1 A JOINT RESOLUTION directing the Department for Medicaid Services to request
2 guidance from the Centers for Medicare and Medicaid Services for Medicaid coverage on
3 prescription digital therapeutics in the Commonwealth of Kentucky.

4 WHEREAS, the Kentucky Office of Drug Control Policy reported that 1,964
5 Kentuckians died from drug overdoses in 2020, a 49 percent increase from the 1,316
6 overdose deaths in 2019; and

7 WHEREAS, the coronavirus pandemic has further challenged access to in-person
8 treatment for Kentuckians in recovery for substance and opioid use disorders; and

9 WHEREAS, the Kentucky Opioid Response Effort has piloted the use of
10 prescription digital therapeutics (PDTs) with successful results in Kentucky; and

11 WHEREAS, PDTs are a new software-based treatment designed to directly treat
12 disease; and

13 WHEREAS, PDTs provide clinicians and patients with evidence-based remote
14 treatment modalities to treat substance and opioid use disorders, mental health disorders,
15 and other diseases and conditions; and

16 WHEREAS, PDTs give patients a discreet, 24 hours per day, 7 days a week tool to
17 complement remote or in-office addiction therapy and provide patients with around-the-
18 clock interventions to treat substance use disorder and opioid use disorder during critical
19 hours when access to in-person support may be unavailable; and

20 WHEREAS, PDTs is a Class II medical device authorized by the United States
21 Food and Drug Administration for treatment of substance use or opioid use disorder;

22 NOW, THEREFORE,

23 ***Be it resolved by the General Assembly of the Commonwealth of Kentucky:***

24 ➔Section 1. The Department for Medicaid Services shall request guidance from
25 the Centers for Medicare and Medicaid Services on coverage and reimbursement of
26 prescription digital therapeutics for use in the Medicaid program no later than 30 days
27 from the effective date of this Act.

1 ➔Section 2. As part of the guidance request, the Department for Medicaid
2 Services shall request:

3 (1) Acceptable methods to cover prescription digital therapeutics, including but
4 not limited to the utilization of the Medicaid program's existing pharmacy benefit, the
5 coverage of durable medical equipment under the Medicaid program, or other
6 mechanisms suggested by the Centers for Medicare and Medicaid Services; and

7 (2) Whether federal financial participation is available for coverage and
8 reimbursement of prescription digital therapeutics in the Medicaid program.

9 ➔Section 3. The Department for Medicaid Services shall provide a report
10 summarizing the status of the Centers for Medicare and Medicaid Services' guidance and
11 response on whether the state can claim federal participation for coverage of and payment
12 for certain prescription digital therapeutics approved by the United States Food and Drug
13 Administration to the Interim Joint Committee on Health, Welfare, and Family Services,
14 the Medicaid Oversight and Advisory Committee, the Legislative Research Commission,
15 and the Kentucky Congressional delegation by December 1, 2022.